Serge Saxonov, Chief Executive Officer and Director of 10x Genomics, Inc., filed a Form 4 on August 26, 2026, reporting the sale of 18,545 shares of Class A Common Stock on August 24, 2026, to cover tax withholding obligations connected to the vesting of restricted stock units.

Key Highlights

  • Shares sold: 18,545 shares of Class A Common Stock disposed of on August 24, 2026, with transaction code S.
  • Weighted average sale price: $63.0237 per share, with individual trades ranging from $63.0088 to $63.78, inclusive.
  • Purpose: According to the filing, shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
  • Direct ownership following transaction: 1,085,835 shares of Class A Common Stock held directly.
  • Indirect holdings: 27 shares held via the Andromeda Trust, 213,250 shares via the Y/S Descendants' Trust, and 71,644 shares via the Y/S Pot Trust, each of which Saxonov serves as trustee.
  • Ticker and exchange: NASDAQ:TXG

Saxonov RSU Vesting Triggers Tax-Related Share Sale at 10x Genomics

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Serge Saxonov, who serves as both Chief Executive Officer and Director of 10x Genomics, Inc. (NASDAQ:TXG), disposed of 18,545 shares of Class A Common Stock on August 24, 2026. The filing states the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, a mechanism commonly used by companies to satisfy tax liabilities on equity compensation.

The transaction was executed across multiple trades. The filing reports a weighted average sale price of $63.0237, with individual trade prices ranging from $63.0088 to $63.78, inclusive. The filing further states that Saxonov undertakes to provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer, or a security holder.

Following the reported transaction, Saxonov directly holds 1,085,835 shares of Class A Common Stock. In addition, the filing discloses indirect beneficial ownership in three trusts for which Saxonov serves as trustee: the Andromeda Trust holding 27 shares, the Y/S Descendants' Trust holding 213,250 shares, and the Y/S Pot Trust holding 71,644 shares. The Form 4 was signed by Randy Wu as Attorney-in-Fact for Serge Saxonov and filed on August 26, 2026.

What Was Disclosed

The filing reports a single open-market sale of 18,545 Class A Common Stock shares by 10x Genomics CEO Serge Saxonov on August 24, 2026, at a weighted average price of $63.0237, executed to satisfy tax withholding requirements on vested restricted stock units.